BioNTech/Pfizer COVID Vaccine Approved for Young Children
Ticker: BNTX · Form: 6-K · Filed: Aug 27, 2025 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Aug 27, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, vaccine, pediatrics
TL;DR
FDA approves BioNTech/Pfizer COVID vax for kids 6mo-4yrs!
AI Summary
On August 27, 2025, BioNTech SE and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved their supplemental Biologics License Application (sBLA). This approval is for the use of their mRNA COVID-19 vaccine, COMIRNATY, in children 6 months through 4 years of age who have received a primary series of the vaccine.
Why It Matters
This FDA approval expands the eligible population for the COMIRNATY vaccine, potentially increasing vaccination rates among a younger demographic and contributing to public health efforts against COVID-19.
Risk Assessment
Risk Level: low — This filing is an announcement of regulatory approval, which is generally positive news with limited immediate downside risk.
Key Players & Entities
- BioNTech SE (company) — Registrant and co-developer of vaccine
- Pfizer Inc. (company) — Co-developer of vaccine
- U.S. Food and Drug Administration (company) — Regulatory body granting approval
- COMIRNATY (product) — Name of the mRNA COVID-19 vaccine
- August 27, 2025 (date) — Date of announcement and approval
FAQ
What specific age group is covered by the supplemental Biologics License Application approval?
The approval covers children 6 months through 4 years of age.
What is the name of the vaccine that received approval?
The vaccine is named COMIRNATY.
Which regulatory body granted the approval?
The U.S. Food and Drug Administration (FDA) granted the approval.
Who are the companies involved in the announcement of this approval?
BioNTech SE and Pfizer Inc. announced the approval.
On what date was this supplemental Biologics License Application approved?
The supplemental Biologics License Application was approved on August 27, 2025.
Filing Stats: 308 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2025-08-27 16:44:32
Filing Documents
- form6-klp81xadaptedfdaappr.htm (6-K) — 15KB
- a991250827_covid-19lp815fd.htm (EX-99.1) — 58KB
- image_0.jpg (GRAPHIC) — 32KB
- image_1.jpg (GRAPHIC) — 69KB
- 0001776985-25-000053.txt ( ) — 212KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On August 27, 2025, BioNTech SE and Pfizer Inc. announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY LP.8.1 COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19 . The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Ramn Zapata-Gomez By s Dr. Sierk Poetting Name Ramn Zapata-Gomez Name Dr. Sierk Poetting Title Chief Financial Officer Title Chief Operating Officer Date August 27, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Pfizer and BioNTech's COMIRNATY Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19